Alnylam Pharmaceuticals

Email address and contacts

Alnylam Pharmaceuticals company description

To those who say “impossible, impractical, unrealistic,” we say: “CHALLENGE ACCEPTED.” Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring RNAi-based medicines to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Alnylam is turning scientific possibility into reality - in 2018, the FDA and EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. We now have three additional medicines on the market: GIVLAARI (givosiran), OXLUMO (lumasiran) and LEQVIO (inclisiran) in partnership with Novartis). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,700 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science Magazine Top Employer 3 years in a row ('19-'21), a Boston Globe Top Place to Work 7x in a row ('15-'21) and one of Fast Company's Best Workplaces for Innovators for 2021. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America. We invite you to connect with us by following us on LinkedIn, Twitter (@Alnylam), Instagram (@AlnylamPharma) and YouTube. See our community guidelines: https://bit.ly/2FcRhJy

Key Employees

?
************
Supply Chain/Manufacturing Planning Co-op
Find Email
D
Dr Akshay Vaishnaw
President
G
Guodong Hui
Principal CMC Biostatistician
D
Diane M
Senior Director, Marketing Excellence & Meetings Management
A
Arundhati Ramani
Manager, CMC Project Management
V
Vivian Wu
Talent Acquisition Coordinator
N
Nick Bucur
Engineer, Manufacturing Technical Services
Sign up to open these and 5 more emails in Alnylam Pharmaceuticals
Message error line

Alnylam Pharmaceuticals competitors and alternatives

Myriad Genetics
Biotechnology
2270 employees
Miltenyi Biotec
Biotechnology
2244 employees
AGC Biologics
Biotechnology
2225 employees
The Jackson Laboratory
Biotechnology
1957 employees
Foundation Medicine
Biotechnology
1886 employees
Kemin Industries
Biotechnology
1690 employees
View all competitors

Recently updated team members of Alnylam Pharmaceuticals

K
Kelley Boucher
Chief Human Resources Officer
P
Pj Arnold
Medical Science Liaison
A
Akanksha Mittal
Senior Director, Rare Disease Lead, US Medical Affairs
H
Heather Swech
Senior Director, Global Patient Discovery CoE
P
Paul Medeiros
Associate Director, Manufacturing
G
Gilles Bertrand
Vice President, Head of Regional Commercial
View all employees

GetProspect Email Finder

Retrieve thousands of email addresses in single click without leaving your current tab. Download for free now!

50 Free emails every month

Add to Chrome

500+ reviews 60,000+ users

Ready to get started?

Try GetProspect email finder for free, and explore all the tools you need to scale your business

Real data
No credit card needed
Leave any time
Find Emails